SHANGHAI – U.S.-China biotech CASI Pharmaceuticals Inc. initiated dosing in Chinese patients with ENMD-2076, a selective angiogenic kinase inhibitor, in a phase II study for triple-negative breast cancer (TNBC). That marks CASI's first foray with ENMD-2076 in China.